TW200409597A - A yogurt formula capable of inhibiting H. pylori - Google Patents

A yogurt formula capable of inhibiting H. pylori Download PDF

Info

Publication number
TW200409597A
TW200409597A TW91134913A TW91134913A TW200409597A TW 200409597 A TW200409597 A TW 200409597A TW 91134913 A TW91134913 A TW 91134913A TW 91134913 A TW91134913 A TW 91134913A TW 200409597 A TW200409597 A TW 200409597A
Authority
TW
Taiwan
Prior art keywords
bacteria
chinese
english
milk
yogurt
Prior art date
Application number
TW91134913A
Other languages
Chinese (zh)
Other versions
TWI252736B (en
Inventor
Li-Wei Chen
Ting-Min Chen
Jin-Sheng Lin
Original Assignee
Uni President Entpr Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni President Entpr Corp filed Critical Uni President Entpr Corp
Priority to TW91134913A priority Critical patent/TWI252736B/en
Publication of TW200409597A publication Critical patent/TW200409597A/en
Application granted granted Critical
Publication of TWI252736B publication Critical patent/TWI252736B/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a process for preparing a yogurt, which comprises adding 10<SP>5</SP> CFU/ml-10<SP>9</SP> CFU/ml of Bifidobacteria lactis Bb-12 to perform fermentation, and adding 0.02%-0.08% of Galactosyl Lactose to effectively maintain the number of B bacteria near the end of the storage period and help the B bacteria in exhibiting the probiotics functions thereof and inhibiting H. pylori.

Description

200409597200409597

發明說明應敘明··發明所屬之技術領域、先前技術 【發明所屬之技術領域】 内容、實施方式及囷式簡單說明) 本發明係於-般優路乳之配方製程t,添加雙岐桿菌师她 ⑹射叫攸删CFU/mi進行發酵,並添加半乳糖寡糖〇 〇2% -〇规,以有效維持B菌在保存末期的菌數,且幫助B紐揮益生菌功 效’達到抑制胃幽門螺旋桿菌之優赂乳配方。 【先前技術】 胃幽門職桿菌(//·处㈣是胃中的害菌,它可在胃中存活且耐胃酸。 根據醫學研究資料胃聞螺旋桿时造紐性胃炎,且是引發消化性潰癌 的致病因子之-。另外有些文獻認為此菌與胃癌或胃· 淋巴癌也有關係。基 於健康的飲食是維護個人終生適當健康的_環,所以我們設計於製造優赂 乳之配方中,添加含有嗜蝮乳样菌Lact〇bac転acid_ilus La5 (A菌)反 雙岐桿菌邮祕⑽mw沉他胳72 (B菌)之AB優酪乳,由於雙岐桿菌 邮—⑽mWa池脉72 (B菌)有抑制幽門螺旋桿菌菌數之功效。據調查 日本特開2001-000143明治乳業也以L.gasseri 21為機能菌種,來訴求相同 之效果,但兩種菌種,屬性完全不同,實與本專利之菌種有顯著的不同, 因此本創意有新穎性。 【内容】 本產品之製程 A. 菌種部份 先行以5L三角瓶裝2.5L水(含葡萄糖)以121°C,15niin,進行滅菌,冷卻 至室溫,添加500U的菌粉AB (A菌;嗜酸乳桿菌及B菌;雙歧桿菌),B菌主 要是當作機能菌種。 B. 糖液部份 200409597 特砂、果^先以85°C熱水經高速粉碎機溶解攪拌1〇分鐘,之後再加入高果 糖液糖、半乳糖寡醣’攪拌均勻後經冷卻板片冷卻至1〇〇c以以10〇c保 存以備用。 C.培地部份 先以85 C熱水溶解乳蛋白之後再加入經脂肪分離的生乳,攪拌後再溶解脫 脂奶粉與酵母粉,再攪拌15分鐘使其完全水合,調配後產品進行均質,均 質壓力為150kg/cm2,均質後進行高溫短時間殺菌,即為培地· 將種部份、Μ唐液部份、1 培地部份準備妥基德,首先將將殺菌後 的奶水(C)的部分打入發酵桶,再將菌種(Α)進行種菌,於發酵溫度為4〇它 的發酵槽進行發酵,約6-7小時之後達一定酸度後,再進行冷卻,冷卻後並 與糖液部份(Β)進行混合,充分攪拌後再以均質壓力2〇〜5〇kg/cm2進行均 質,均質後進行充填,此時之乳酸菌總數達1〇8 CFU/ml以上,B菌達 107CFU/ml,即製成本產品。 【實施方式】 先將500U的菌粉ABT-2、500U的菌粉ABT-4與50U的LB-12菌粉充 分溶解分散於滅菌水60%中,内含/ac饴册io5einj/mi、The description of the invention should be stated ... The technical field to which the invention belongs, the prior art [Technical field to which the invention belongs] Brief description of the contents, embodiments and formulae) The present invention is a formula t of the general road milk, adding Bifidobacterium She shot and called Youyou CFU / mi for fermentation, and added galactose oligosaccharides 0.02%-0 to effectively maintain the number of bacteria at the end of the preservation period, and help B's probiotic efficacy to achieve inhibition Breast milk formula of Helicobacter pylori. [Prior technology] Pylori bacillus (// · Chrysostomium is a harmful bacterium in the stomach, it can survive in the stomach and is resistant to gastric acid. According to medical research data, gastroenteritis is caused when the spiral rod is smelled, and it causes digestion One of the causative factors of cancer-breaking. In addition, some literatures believe that this bacteria is also related to gastric cancer or gastric and lymphoma. A healthy diet is to maintain an individual's proper health throughout life, so we designed it in the formula of superior milk. , Add AB milky milk containing Lact〇bac 転 acid_ilus La5 (A bacteria) anti-Bifidobacterium spp. Mw Shenta 72 (B bacteria), due to Bifidobacterium maili⑽mWa 池 脉 72 ( B) has the effect of inhibiting the number of H. pylori bacteria. According to a survey, Japanese Patent Application Laid-Open No. 2001-000143 Meiji Dairy also uses L. gasseri 21 as a functional strain to seek the same effect, but the two strains have completely different properties. It is significantly different from the strains of this patent, so the original idea is novel. [Content] The process of this product A. The strains are first filled with 5L triangular bottle of 2.5L water (containing glucose) at 121 ° C, 15niin. , Sterilize and cool to room temperature Add 500U of bacterial powder AB (A bacteria; Lactobacillus acidophilus and B bacteria; Bifidobacterium), B bacteria are mainly used as functional bacteria. B. Sugar solution part 200409597 Special sand, fruit ^ first at 85 ° C The hot water was dissolved and stirred for 10 minutes by a high-speed pulverizer, and then high fructose liquid sugar and galactooligosaccharides were added and stirred well. After cooling, the plate was cooled to 100c to be stored at 100c for future use. Partially dissolve milk protein in 85 C hot water, then add raw milk separated by fat, stir and then dissolve skim milk powder and yeast powder, stir for 15 minutes to completely hydrate, and homogenize the product after mixing. The homogenizing pressure is 150kg / cm2, sterilize at high temperature for a short time after homogenization, that is, to cultivate the land. Prepare the seed part, M Tang liquid part, and 1 part of the field to prepare Kidder. First, put the sterilized milk (C) part into the fermentation barrel. Then, the strain (A) is seeded and fermented in a fermentation tank at a fermentation temperature of 40. After a certain acidity is reached in about 6-7 hours, it is cooled, and after cooling, it is mixed with the sugar solution part (B). After mixing, stir well and then homogenize with a homogenizing pressure of 20 to 50 kg / cm2 After homogenization and filling, the total number of lactic acid bacteria reached more than 108 CFU / ml and B bacteria reached 107 CFU / ml. This is the product. [Embodiment] First 500U of bacterial powder ABT-2, 500U of bacterial powder ABT-4 and 50U LB-12 bacteria powder are fully dissolved and dispersed in 60% of sterilized water, which contains / ac 饴 饴 io5einj / mi,

Lactobacillus acidophilusl05CFU/ml將菌種接種於發酵培地,而該發酵培地 /' 為將含有水溶解乳蛋白0.16%、脂肪分離的生乳23%、脫脂奶粉7·8%與酵 母粉0.09%,殺菌後將奶水打入發酵桶,於發酵溫度4〇°C進行發酵,約卜7 小時之後,再進行冷卻,冷卻後加入糖液進行混合,此糖液為特砂5 2%、 果膠0.5%以85°C熱水經高速粉碎機溶解攪拌10分鐘,再加入高果糖液糖 3.2%、半乳糖寡醣0.05%,攪拌均勻後,均質壓力為20-50kg/cm2,均質後 進行充填,此時總乳酸菌數達1〇8 CFU/ml以上,即製成本產、品。 實驗方法舆結果 l.13c呼吸法檢測: 200409597 穩定同位素碳·13標蛾之尿素 75西西,讓受檢者經過隔夜的禁食後口 服入胃,收集受測者在口服尿素前及之後三十分鐘呼出之氣體,利用氣體色 層分析同位素比質譜儀(GCIRMS,ΑΡ2〇〇3)來分析比較前後兩侧定值, 比基準值差值比率大於3.5判定為陽性,即可診斷出受測者是否有幽門螺 旋桿菌感染。結果如圓一所示。每日喝含有Β菌之優酪乳,一日兩瓶共 440ml,八週後可以有效降低胃中幽門螺旋桿菌之菌數,且停喝優酪乳一個 月後(12週),受試者胃中菌數並無明顯增加,與食用優酪乳之前才目比,仍 有統計上的差異(Ρ&lt;0·05),表示優酪乳抑制胃幽門螺旋桿菌之功效至少可 維持一個月。 囷一優酪乳抑制幽門螺旋桿之人體實驗 p &lt; 0.05 80604020 ocplixaLactobacillus acidophilusl05CFU / ml was used to inoculate the bacteria on the fermented cultivation site, and the fermented cultivation site / 'was to contain 0.16% of water-soluble milk protein, 23% of raw milk separated from fat, 7.8% of skimmed milk powder and 0.09% of yeast powder. The milk is poured into a fermentation barrel, and fermentation is performed at a fermentation temperature of 40 ° C. After about 7 hours, it is cooled. After cooling, the sugar liquid is added to mix. The sugar liquid is 5% of special sand, 0.5% of pectin and 85%. The hot water at ° C is dissolved and stirred for 10 minutes by a high-speed pulverizer, and then high fructose liquid sugar 3.2% and galactose oligosaccharide 0.05% are added. After stirring well, the homogenizing pressure is 20-50kg / cm2, and the filling is performed after homogenization. When the number of lactic acid bacteria reaches more than 108 CFU / ml, the product and product are made. Experimental method public results l.13c breathing test: 200409597 Stable isotope carbon · 13 standard moth urea 75 Sicis, subject to oral fasting after overnight fasting, collect subject 30 before and after oral urea The gas exhaled in minutes is analyzed with a gas chromatographic isotope ratio mass spectrometer (GCIRMS, AP2003) to analyze and compare the fixed values on the front and back sides. If the ratio is greater than 3.5, it is determined to be positive, and the test subject can be diagnosed. Whether there is a Helicobacter pylori infection. The results are shown in circle one. Drink 440 ml of Yogurt containing B bacteria daily, two bottles a day for a total of 440ml. After eight weeks, the number of Helicobacter pylori in the stomach can be effectively reduced, and one month (12 weeks) after stopping the yogurt, the subject There was no significant increase in the number of bacteria in the stomach, and there was still a statistical difference (P &lt; 0.05) compared with the ratio before the consumption of yogurt, indicating that the effectiveness of yogurt in inhibiting gastric Helicobacter pylori can be maintained for at least one month. Human experiment on the inhibition of pyloric spiral rods by Daiichi Yogurt p &lt; 0.05 80604020 ocplixa

2.發炎因子的分析 胃液素原(Pepsinogen )是胃液中的酸性蛋白分解酵素之胃液素不活性型 前驅體’可分成Group I pepsinogen及Group丨丨pepsinogen。我們利用針 對PG丨&amp;丨丨的特異單株抗體所使用的丨RMA(丨mmunoradiometricAssay) kit來測定血液中的PG| &amp;丨丨值。在胃黏膜發炎的情況下,pG丨丨上升幅度 較PGI大,所以分析pgi川的比值會降低,用來評估胃内黏膜發炎情況。 結果如圖二所示。每日喝含有B菌之優酪乳,一日兩瓶共440ml,八週後 可以有效降低胃部的發炎情形,且停喝優酪乳一個月後(12週),受試者胃 中發炎情形仍無惡化,與食用優酪乳之前相比發炎情形有改善(p&lt;〇〇5)表 示優酪乳抑制胃部發炎之功效至少可維持一個月。 圓二•優酪乳降低胃部發炎因子之人體實驗2. Analysis of Inflammatory Factors Pepsinogen is a gastrin-inactive precursor of acidic proteolytic enzyme in gastric juice, which can be divided into Group I pepsinogen and Group 丨 pepsinogen. We used the RMA (丨 mmunoradiometricAssay) kit for specific monoclonal antibodies against PG 丨 &amp; 丨 丨 to determine the PG | &amp; 丨 value in blood. In the case of gastric mucosal inflammation, the increase of pG 丨 丨 is larger than that of PGI, so the ratio of pgichuan will be reduced to evaluate the inflammation of gastric mucosa. The results are shown in Figure 2. Drink 440ml of Yogurt containing B bacteria daily, two bottles a day, a total of 440ml. After eight weeks, it can effectively reduce the inflammation of the stomach. After stopping drinking yogurt for one month (12 weeks), the subject's stomach becomes inflamed. The situation has not worsened, and the inflammation has improved compared to before the consumption of yogurt, (p &lt; 0.05), indicating that the effectiveness of yogurt to suppress stomach inflammation can be maintained for at least one month. Yuan Er • Yu Dairy Milk Reduces Human Inflammatory Factors in Humans

3·提高治癒率舆降低服藥的副作用 感染幽門螺方疋杯固的患者皆以三合一的抗生素治療,但治癒率不夠高, 且會產生許多的副作用如·、«、食愁不振·.等,以上缺失,我們 概路乳搭配抗生素來輔助治療有胃炎、胃潰瘍疾病的患者,餅受試者 分成兩組並皆給找生素治療,另^再輔以祕乳共同治療,一日兩瓶 200409597 持續喝兩個月,再比較治癒率與副作用的改善情形如表一與表二所示。 表一 •優酪乳提高三合一抗生素治療率之人體實驗3. Improve the cure rate and reduce the side effects of medication. Patients infected with Helicobacter pylori square cup solids are treated with three-in-one antibiotics, but the cure rate is not high enough, and there will be many side effects such as ·, «, anxiety and anxiety. Etc., the above is missing, we have an overview of breast milk with antibiotics to assist the treatment of patients with gastritis and gastric ulcer disease. The subjects of the cake were divided into two groups and all were treated with biotin. Bottle 200409597 drink for two months, and then compare the cure rate and improvement of side effects as shown in Table 1 and Table 2. Table 1 • Human experiment to improve the rate of three-in-one antibiotic treatment with yogurt

Eradication rate, % ⑽ (95% conftdenice interval)Eradication rate,% ⑽ (95% conftdenice interval)

Per protocol un^lym iiitentioii-to^treat eaaly 你 1Mple-j&gt;Ius-y〇g«rt 93.5 (73/77) 913 (73/80)&quot; group (89,5-97,3) (88,8-94.2) Triple-only group 88.9 m/72) (US-92.B) 78 J (63/801 (73.9-B2J) 如表一所示,以TT(intention_to-treat)分析法來判別9有喝優絡乳那組治癒 率有明顯提高(91.3% v.s 78.3°/。),並且有統計上意義(p值&lt;0.05)。 表二優酪乳降低服築副作用且增加服藥順從度之人鱧實驗Per protocol un ^ lym iiitentioii-to ^ treat eaaly you 1Mple-j &gt; Ius-y〇g «rt 93.5 (73/77) 913 (73/80) &quot; group (89,5-97,3) (88, 8-94.2) Triple-only group 88.9 m / 72) (US-92.B) 78 J (63/801 (73.9-B2J)) As shown in Table 1, TT (intention_to-treat) analysis method is used to determine whether there is 9 The cure rate of the Youluoru group had a significant improvement (91.3% vs 78.3 ° /.), And it was statistically significant (p value &lt; 0.05). Table 2 People with buttermilk reduce side effects and increase compliance鳢 Experiment

Variable Tt部細 vyogurt gnmp (» 8()) TripliKwIy gwup {r·二 80&gt; P age (years) 47.8 45.9 Fmaks, % in) 50 H(}) 52.5 (4¾ HS, &amp;uk&gt;scopic findings, % (») Oastrlc ulcer 15 U2) 20(16) ns. Duodena! ulcer 45 (28} .15 (28) Non^uiccr gaAlrodxicnlciiitie 50 (40) C細卿iu:蛉從ilii 細3:哪、%⑻ 40 [m m. Full {? days} 67.S (54) 43 邱 5} &lt; (W)5 ihxHi {&gt; 5 mu\ &lt; 7 days) 2S.8 (2¾ 46.2 〇7) Foot (&lt; 5 days) 2.S (2) IS⑶ 似 Drq^out 1J(” 6;2 (5) Nausea S 8 HS. VcmiSIliifi :1. 7 &lt; 0Λ5 Consii㈣細 1 H &lt; 0-05 Di 这 rrhoc 这 2 10 &lt; (im .5 n &lt; 0.05 BHtcmcss of mouth 2 s n MM li^adad^&amp; :1. 4 Subtotal IS Si &lt; (W)S 200409597 表二所示,持績喝優酪乳兩個月可以有效降低服用抗生素所產生的副作 用,並增加服藥的順從度皆有統計上的意義(P&lt;0.05)。 4·乳酸菌感受性測試Variable Tt Department vyogurt gnmp (»8 ()) TripliKwIy gwup (r · 二 80 &gt; P age (years) 47.8 45.9 Fmaks,% in) 50 H ()) 52.5 (4¾ HS, &amp; uk &gt; apparent findings,% (») Oastrlc ulcer 15 U2) 20 (16) ns. Duodena! Ulcer 45 (28) .15 (28) Non ^ uiccr gaAlrodxicnlciiitie 50 (40) C 卿卿 iu: 蛉 From ili 细 3: Where,% ⑻ 40 [m m. Full {? days} 67.S (54) 43 邱 5} &lt; (W) 5 ihxHi {&gt; 5 mu \ &lt; 7 days) 2S.8 (2¾ 46.2 〇7) Foot (&lt; 5 days) 2.S (2) IS⑶ like Drq ^ out 1J ("6; 2 (5) Nausea S 8 HS. VcmiSIliifi: 1.7 &lt; 0Λ5 Consii㈣ 1 1 & &lt; 0-05 Di This rrhoc this 2 10 &lt; (im .5 n &lt; 0.05 BHtcmcss of mouth 2 sn MM li ^ adad ^ &: 1. 4 Subtotal IS Si &lt; (W) S 200409597) Months can effectively reduce the side effects caused by taking antibiotics, and increase the compliance of taking medications are statistically significant (P &lt; 0.05). 4. Lactic acid bacteria sensitivity test

將HP的臨床菌株1號塗滿於brucella agar上,再將不同的乳酸菌a菌、B 菌、嗜熱鏈球菌、保加利亞桿菌經隔夜培養再將培養液滴0 04ml於disc上, 待disc完全吸收菌體後將disc貼於plate上,2〜3天後觀察其抑制圈之大小。 如圖三所示’體外實驗證實優酪乳中的B菌可以有效抑制幽門螺懸桿菌的 生長,且濃度越高抑制效果越佳,但優酪乳其他的乳酸菌如:A菌、嗜熱鏈 球菌、保加利亞桿菌皆無此效果。 圏三·Β菌對胃幽門螺旋桿菌之體外抑制圈實驗 J 21J1 2 (&lt;fe&lt;kc«lr «宙S耸 L 一 ο 度 濃 的 .菌 /Β s•優酪乳的抑菌測試 將適量濃度的優酪乳如(0.1〜5ml)與培養基(含胎牛血清)進行混合,待培養基 凝膠後,滴入5//1具活性的幽門螺旋桿菌臨床菌株!與2,用分光光度計 剛定調整菌數,菌數約為lx 108CFU/m卜再以特殊氣體培養,培養2〜3 天,之後觀察幽門螺旋桿菌是否生長,若無生長即判定此濃度優路乳具有 抑制HP之功效。 200409597 表三·優酪乳對胃幽門螺旋桿菌的髏外抑菌實轮 無B菌之優酪乳(只有三株菌) 含四株菌之優酪乳 HP臨床菌株 1 &gt;5ml皆無抑菌效果 只要0.125ml就有抑菌效果 HP臨床菌株 2 &gt;5ml皆無抑菌效果 只要0.125ml就有抑菌效果 添加Bifidobacteria lactis Bb-12 與沒有添加 Bifidobacteria lactis Bb-12 之優路 乳相比較;可以確定B菌的存在的確是具功效性的有效成分。 【圓式簡單說明】 □續次頁 (發明說明頁不敷使用時,請註記並使用續頁)Spread HP clinical strain No. 1 on brucella agar, and then culture different lactic acid bacteria a, B, Streptococcus thermophilus, and B. bulgaricus overnight, and then drop 0 04ml of culture liquid on disc, and wait for disc to completely absorb After the bacteria were placed on the plate, the size of the inhibition circle was observed after 2 to 3 days. As shown in Figure 3, in vitro experiments have confirmed that B bacteria in yogurt can effectively inhibit the growth of Helicobacter pylori, and the higher the concentration, the better the inhibition effect, but other lactic acid bacteria in yogurt, such as: A bacteria, thermophilic chain Neither cocci nor bulgaric bacteria have this effect.圏 三 · Β bacteria in vitro inhibition of Helicobacter pylori in vitro J 21J1 2 (&felt; fec &lt; kc «lr An appropriate amount of yogurt (such as 0.1 ~ 5ml) is mixed with the culture medium (containing fetal bovine serum). After the culture medium is gelled, 5 // 1 of the active Helicobacter pylori clinical strain is added dropwise! And 2, use spectrophotometry The number of bacteria was adjusted to determine the number of bacteria. The number of bacteria was about lx 108 CFU / m, and then cultured with a special gas for 2 to 3 days. Then, observe whether H. pylori grows. 200409597 Table 3. Yogurt's effect on Helicobacter pylori's extracorporeal bacteriostasis. Bacterial free Bacterial buttermilk (only three strains) Yogurt with four strains of HPL clinical strain 1 &gt; 5ml None Antibacterial effect as long as 0.125ml has bacteriostatic effect HP clinical strain 2 &gt; 5ml has no antibacterial effect as long as 0.125ml has antibacterial effect Add Bifidobacteria lactis Bb-12 compared with the best way milk without Bifidobacteria lactis Bb-12 It can be confirmed that the presence of B bacteria is indeed a valid and effective agent . [Circular simple description] □ Continued next page (page explanation invention shortage of space, make annotation and use continuation sheet)

Claims (1)

200409597 串請糊範窗 1 · 一種可抑制胃幽門螺旋桿菌之優酪乳配方,其配方係添加水份60%、 含有水溶解乳蛋白0.16%、脂肪分離的生乳23%、脫脂奶粉7·8%與酵母粉 0·09% ,於發酵冷卻後再加入糖液進行混合,此糖液為特砂5 2%、果膠 〇·5%、高果糖液糖3.2%、半乳糖寡醣〇·〇2〇/ο_0·08%、雙岐桿菌論灿 1()5CFU/ml 一 10 9 CFU/ml,其特徵在於添加雙岐桿菌 (卹/咖脉仰1〇5CFU/ml—1〇9cFU/m!及添加半乳糖寡糖 0.02%-_%,財效轉B齡保存末_ ,且幫助b紐揮益生 菌功效,達到抑制胃幽門螺旋桿菌之優酪乳配方。 1 修w ........ 200409597 (填寫本書件時請先行詳M申請書後之申請須知,作※記號部分請勿填窝) 浓申請案號:^PC 分類:_ ※申請日期:9 Μ 2〜乙200409597 Symptoms 1 · A buttermilk formula that inhibits Helicobacter pylori, which is formulated with 60% water, 0.16% water-soluble milk protein, 23% raw milk with fat separation, and skimmed milk powder 7.8 % And yeast powder 0.09%. After fermentation and cooling, sugar solution is added and mixed. This sugar solution is special sand 52%, pectin 0.5%, high fructose liquid sugar 3.2%, and galactooligosaccharides. 〇2〇 / ο_0.08%, Bifidobacterium noncan 1 (5 CFU / ml-10 9 CFU / ml, which is characterized by the addition of Bifidobacterium (shirt / Camai Yang 105 CFU / ml-10 cFU / ml m! and the addition of galacto-oligosaccharides 0.02% -_%, the financial effect is transferred to the end of B-year preservation, and it helps b to probiotic effect, to achieve the optimal buttermilk formula for inhibiting gastric Helicobacter pylori. 1 repair w ... ..... 200409597 (Please fill out the application notes after completing the application form, fill in the ※ mark part, please do not fill in the nested part) Thick application case number: ^ PC Category: _ ※ Application date: 9 Μ 2 ~ B 明名稱__ . ,靈麵 議纖戀纖賴議1議議 (中文)一種可抑制胃幽門螺徙桿菌之優酿|丨.航方 (英文)_ — 一 ΙΙΙβ……… · :· _麵人(炎1人)- (如發明人超過-人,請填說明書發明人績頁) 姓名:(中文) 陳立偉_— 住居所地址:(中文)台南市大學路22辰Π摅夕ΠΠ (英文)_ 丄英文) Xfe) 國籍:C中文)中華民國 參'申請人(共ζιΛ) 申績人如發明人超過一人,請填說明書申請人續頁) 姓名或名稱:(中文)統一企業股份有限公§| 英文) ——中正路Ming name __., Ling face discussion fiber love fiber lai ye yi yi yi yi yi yi yi (Chinese) An excellent wine that can inhibit gastric pyloric bacillus bacillus | 丨 Hangfang (English) _ — ΙΙΙβ ……… ·: _ Face person (1 person in inflammation)-(If the inventor exceeds-person, please fill in the inventor ’s performance page) Name: (Chinese) Chen Liwei _— Address of residence: (Chinese) 22 Chen University Road, Tainan City Π 摅 夕 ΠΠ ( (English) _ XEnglish) Xfe) Nationality: C Chinese) ROC applicants (total ζιΛ) If the applicant is more than one inventor, please fill in the description of the applicant's continuation page) Name or name: (Chinese) Uniform Enterprise Co., Ltd. § | English) ——Zhongzheng Road □讀發明人或申請人續頁(發明人或申請人棚位不敷使用時,請註記並使用續頁) 國籍:C中文)中華邑网 代表人:(中文^ (英文) 200409597□ Read continuation pages of the inventor or applicant (Please note and use the continuation page when the inventor or applicant's shed is insufficient.) Nationality: C Chinese) Zhonghuayi Network Representative: (Chinese ^ (English) 200409597 發明人 2 姓名:(中文)_陳婷玟 (英文)__ 住居所地址:(中文)高雄市芩雅區五福里31鄰大順三路282巷77弄9號 (英文)__ 國籍:(中文)中華民國_(英文)__ 翻人 3 姓名:(中文) 林金生 _ (英文)___ 住居所地址:(中文)台南市南區開南里17鄰新建路26巷5號之3 (英文)__ 國籍:(中文) 中華民國_(英文) _ 發明人 4 姓名:(中文)__ (英文)___ 住居所地址:(中文)_ (英文)_ 國籍:(中文)_(英文) 發明人 5 姓名:(中文)_ (英文)_ 住居所地址:(中文)_ (英文)_ 國籍:(中文)_(英文) 發明人 6 姓名z(中文)_ (英文) _ 住居所地址:(中文)_ (英文)__ 國籍:(中文)_(英文) 200409597 (發明说明麁•眷明所屬之技術領域、先前技術、内容、實施方式及囷式簡單說明) 【發明所屬之技術領域】 禮 本發明係於一般優路乳之配方製程中,添加雙岐桿菌 /ac沿脉切105CFU/mi—109CFU/ml進行發酵,並添加半乳糖募糖〇 〇2% 一0.08%,以有效維持B菌在保存末期的菌數,且幫助B菌發揮益生菌功 效,達到抑制胃幽門螺旋桿菌之優酪乳配方。 【先前技術】 胃幽門螺旋桿菌是胃中的害菌,它可在胃中存活且耐胃酸。 根據醫學研究資料胃幽門螺旋桿菌會造成慢性胃炎,且是引發消化性溃瘍 的致病因子之一。另外有些文獻認為此菌與胃癌或胃淋巴癌也有關係。基 於健康的飲食是維護個人終生適當健康的一環,所以我們設計於製造優絡 乳之配方f ’添加含有今蝮乳桿菌Lactobacillus acidophilus La_5 ( Α菌)及 雙咕J干菌Bifidobacieria iactis Bb-J 2 (B镇)之AB優路乳,由於雙故样菌 菌)有抑制幽。螺旋桿菌菌數之功效。據調查 /、 . · 一 日本特開2001_000143日月治乳業也以L.gasseri 21為機能菌種,來訴求相同 之效果,但兩種菌種,屬性完全不同,實與本專利之菌種有顯著的不同, 因此本創意有新穎性。 【内容】 本產品之製程 A.菌種部份 先f以5L一角瓶裝2. 5L水(含葡萄糖)以12TC , 15min ,進行滅菌,冷卻 至至溫,添加500U的菌粉AB (A菌;嗜酸乳桿菌及B菌;雙歧桿菌),β菌主 要是當作機能菌種。 Β.糖液部份 f 200409597 特砂、果膠先以85°C熱水經高速粉碎機溶解攪拌10分鐘,之後再加入高果 糖液糖、半乳糖募醣,攪拌均勻後經冷卻板片冷卻至1(rc以下,以10〇c保 存以備用。 C.培地部份 先以85 C熱水溶解乳蛋白之後再加入經脂肪分離的生乳,视拌後再溶解脫 脂奶粉與酵母粉’再扰拌15分鐘使其完全水合,調配後產品進行均質,均 質壓力為150kg/cm2,均質後進行高溫短時間殺菌,即為培地· 將△·.菌種部份、.擴农部份、C.培地部份準借喜基德,首先將將殺菌後 的奶水(C)的部分打入發酵桶’再將菌種(A)進行種菌,於發酵溫度為4〇cc 的發酵槽進行發酵,約6-7小時之後達一定酸度後,再進行冷卻,冷卻後並 與糖液部份(B)進行混合,充分攪拌後再以均質壓力20〜5〇kg/cm2進行均 質,均質後進行充填,此時之乳酸菌總數達108 CFU/ml以上,B菌達 107CFU/ml,即製成本產品。 【實施方式】 先將500U的菌粉ABT-2、500U的菌粉ΑΒΤΓ4與50U的LB-12菌粉充 分溶解分散於滅菌水 60%中,內含 Bifidobacteria lactis Bb-J2 10sCFU/ml、 % Lactobacillus acidophilusl05CFU/ml將菌種接種於發酵培地,而該發酵培地 為將含有水溶解乳蛋白0.16%、脂肪分離的生乳23%,、脫脂奶粉7 8%與酵 母粉0.09%,殺菌後將奶水打入發酵桶,於發酵溫度40°C進行發酵,約6_7 小時之後,再進行冷卻,冷卻後加入糖液進行混合,此糖液為特砂5 2〇/。、 果膠0.5%以85eC熱水經南速粉碎機溶解搜掉分鐘,再加入高果糖液糖 3.2%、半乳糖寡醣0.05%,攪拌均勻後,均質壓力為20-50kg/cm2,均質後 進行充填,此時總乳酸菌數達1〇8 CFU/ml以上,即製成本產、品。 實驗方法声結果 l.13c呼吸法檢測: 200409597 穩定同位素破·13標幟之尿素試劑75西西,讓受檢者經過隔夜的禁食後口 服入胃,收集受測者在口服尿素前及之後三十分鐘呼出之氣體,利用氣體色 層分析同位素比質譜儀(GCIRMS,AP2003)來分析比較前後兩個測定值, 比基準值差值比率大於3·5判定為陽性,即可診斷出受測者是否有幽門螺 旋桿菌感染。結果如Α1所示。每日喝含有Β菌之優絡乳,一日兩瓶共 440ml ’八週後可以有效降低胃中幽門螺旋桿菌之菌數,且停喝優酪乳一個 月後(12週),受試者胃中菌數並無明顯增加,與食用優酪乳之前相比,仍 有統計上的差異(Ρ&lt;0·05),表示優路乳抑制胃幽門螺旋桿菌之功效至少可 維持一個月。 Α1 ;優酪乳抑制幽門螺旋桿菌之人想實驗 S -p &lt; 0.05 p &lt; 0.05 - 8060 oo 08 θ&lt;! ο ΘΘΟΟ 〇 cx|&lt; ΟΟΟ0Η8Θ Θ 〇 WeekO Λ —Week 4 —Week 12 2.發炎因子的分析 胃液素原(、P印sinogen )是胃液中的酸性蛋白分解酵素之胃液素不活性型 200409597 前驅體’可分成Group I pepsinogen及Group丨丨pepsinogen。我們利用針 對PGI&amp;II的特異單株抗艘所使用的iRMA(immunoradiometricAssay) kit來測定血液中的pgi &amp;丨丨值。在胃黏膜發炎的情況下,pG丨丨上升幅度 較PG丨大,所以分析pg丨川的比值會降低,用來評估胃内黏膜發炎情況。 結果如A2所示。每曰喝含有B菌之優酪乳,一曰兩瓶共44〇m卜八週後可 以有效降低胃部的發炎情形,且停喝優酪乳一個月後(12週),受試者胃中 發炎情形仍無惡化,與食用優酪乳之前相比發炎情形有改善(P&lt;005)表示 優絡乳抑制胃部發炎之功效至少可維持一個月。 A2 ;優酪乳降低胃部發炎因子之人髏實驗Inventor 2 Name: (Chinese) _ 陈婷玟 (English) __ Address of residence: (Chinese) No. 9, Lane 77, Lane 282, Dashun 3rd Road, 31 Fuk Fuli, Kaohsiung District, Kaohsiung (English) __ Nationality: (Chinese) Chinese Republic of China _ (English) __ Fanren 3 Name: (Chinese) Lin Jinsheng _ (English) ___ Address of residence: (Chinese) No. 3, Lane 26, Xinjian Road, 17 Kainanli, South District, Tainan City (English) __ Nationality: ( Chinese) Republic of China _ (English) _ Inventor 4 Name: (Chinese) __ (English) ___ Address of Residence: (Chinese) _ (English) _ Nationality: (Chinese) _ (English) Inventor 5 Name: (Chinese ) _ (English) _ Address of Residence: (Chinese) _ (English) _ Nationality: (Chinese) _ (English) Inventor 6 Name z (Chinese) _ (English) _ Address of Residence: (Chinese) _ (English) ) __ Nationality: (Chinese) _ (English) 200409597 (Explanation of the invention • Brief description of the technical field, prior art, content, implementation and mode of the invention) [Technical field to which the invention belongs] The present invention belongs to the general In the process of formulating Urumu, add bifidobacterium / ac to cut 105CFU along the vein / mi—109CFU / ml for fermentation, and added galactose and 0.02% to 0.08% to effectively maintain the number of B bacteria at the end of storage, and help B bacteria to exert probiotic effects, and to inhibit gastric H. pylori The best buttermilk formula. [Prior technology] Helicobacter pylori is a harmful bacterium in the stomach. It can survive in the stomach and is resistant to gastric acid. According to medical research data, Helicobacter pylori causes chronic gastritis and is one of the causative factors that cause peptic ulcer. In addition, some literatures suggest that this bacterium is also related to gastric cancer or gastric lymphoma. A health-based diet is part of maintaining proper health throughout a person's life, so we designed the formula for the manufacture of Uromilk f 'with Lactobacillus acidophilus La_5 (Α bacteria) and Bifidobacieria iactis Bb-J 2 (B Town) AB You Lu milk, due to double-type fungus bacteria) can inhibit the secretion. The effect of the number of Helicobacter bacteria. According to surveys, · · Japanese Patent Application Laid-Open No. 2001_000143 Riyuezhi Dairy also uses L. gasseri 21 as a functional strain to seek the same effect, but the two strains have completely different properties, which is actually the same as the strains of this patent. Significantly different, so the idea is novel. [Content] The production process of this product A. The bacteria part is firstly packed in a 5L corner bottle, 2.5L of water (containing glucose) is sterilized at 12TC for 15min, cooled to warm, and 500U of bacteria powder AB (A bacteria; Lactobacillus acidophilus and B bacteria; Bifidobacterium), β bacteria are mainly used as functional bacteria. Β. Sugar solution f 200409597 Special sand and pectin are first dissolved in 85 ° C hot water by a high-speed pulverizer and stirred for 10 minutes, and then added high fructose liquid sugar and galactose to raise sugar. After stirring, cool through cooling plate To 1 (rc or less, store at 10 ° C for future use. C. Pedi first dissolve milk protein with 85 C hot water, then add raw milk separated by fat, and then dissolve skim milk powder and yeast powder after mixing. Then disturb Stir for 15 minutes to completely hydrate. After preparation, the product is homogenized. The homogenization pressure is 150kg / cm2. After homogenization, it is sterilized at high temperature for a short time. The cultivated part is borrowed by Hi-Kid. First, the part of the sterilized milk (C) is put into the fermentation barrel, and then the strain (A) is seeded. The fermentation is performed in a fermentation tank with a fermentation temperature of 40 cc. After 6-7 hours, a certain degree of acidity is reached, and then cooling, after cooling and mixing with the sugar liquid part (B), after stirring thoroughly, homogenize with a homogenizing pressure of 20 to 50 kg / cm2, and then fill it after homogenization, At this time, the total number of lactic acid bacteria reached 108 CFU / ml and B bacteria reached 107 CFU / ml. [Embodiment] First, 500U of bacterial powder ABT-2, 500U of bacterial powder ΑΒΤΓ4 and 50U of LB-12 bacterial powder are fully dissolved and dispersed in 60% of sterilized water, which contains Bifidobacteria lactis Bb-J2 10sCFU / ml,% Lactobacillus acidophilusl05CFU / ml inoculate the bacteria on the fermented cultivation ground, and the fermented cultivation ground is the raw milk containing 0.16% of water-soluble milk protein, 23% of fat separated, 78% of skim milk powder and 0.09% of yeast powder, after sterilization Pour milk into the fermentation tank and ferment at 40 ° C. After about 6-7 hours, cool down. After cooling, add a sugar solution to mix. This sugar solution is special sand 5 2 //, pectin 0.5% to The 85eC hot water is dissolved and searched for 5 minutes through the Nansu mill, and then high fructose liquid sugar 3.2% and galactose oligosaccharide 0.05% are added. After mixing well, the homogenizing pressure is 20-50kg / cm2, and the filling is performed after homogenization. The number of lactic acid bacteria reached more than 108 CFU / ml, which made the product and product. Experimental method Acoustic result l.13c Respiratory test: 200409597 Stable isotope breaking · 13-labeled urea reagent 75 Sicis, let the subject pass overnight. Oral into the stomach after fasting The gas exhaled by the subject 30 minutes before and after oral urea was analyzed using a gas chromatographic isotope ratio mass spectrometer (GCIRMS, AP2003) to analyze the two measured values before and after the comparison. The ratio of the difference to the reference value was greater than 3.5. If it is positive, you can diagnose whether the subject has Helicobacter pylori infection. The results are shown in Α1. Drinking 440ml of Yolu milk containing B bacteria daily, two bottles a day, a total of 440ml 'Eight weeks can effectively reduce the pylorus in the stomach The number of bacteria of Helicobacter, and one month (12 weeks) after stopping drinking yogurt, there was no significant increase in the number of bacteria in the stomach of the subject, and there was still a statistical difference compared with before eating yogurt (P &lt; 0.05), which indicates that the effectiveness of Urolactam in inhibiting gastric H. pylori can be maintained for at least one month. Α1; People who inhibited Helicobacter pylori by yogurt and want to experiment S -p &lt; 0.05 p &lt; 0.05-8060 oo 08 θ &lt;! ο ΘΘΟΟ 〇cx | &lt; 〇〇〇0Η8Θ ΘWeekO Λ —Week 4 —Week 12 2. Analysis of Inflammatory Factors Protosporin (Pininogen) is an acidic proteolytic enzyme in the gastric juice, which is a gastrin-inactive type 200409597 precursor, which can be divided into Group I pepsinogen and Group 丨 pepsinogen. We used the iRMA (immunoradiometricAssay) kit for a specific monoclonal antibody against PGI &amp; II to determine the pgi &amp; 丨 value in blood. In the case of gastric mucosal inflammation, pG 丨 丨 rises more than PG 丨, so the analysis of pg 丨 chuan ratio will decrease, which is used to evaluate the gastric mucosal inflammation. The results are shown in A2. Drink two bottles of Yogurt containing B bacteria every day, 44m in total. After eight weeks, it can effectively reduce the inflammation of the stomach, and one month (12 weeks) after stopping drinking buttermilk, the subject's stomach The inflammation condition remained unchanged, and the inflammation condition was improved compared with that before consumption of yogurt (P &lt; 005), indicating that the effect of yogurt inhibiting gastric inflammation can be maintained for at least one month. A2; Human-bone experiment of reducing the inflammation factor of stomach by yogurt 3·乳酸菌感受性測試 將HP的臨床菌株1號塗滿於brucella agar上,再將不同的乳酸菌A菌、B 菌、嗜熱鏈球菌、保加利亞桿菌經隔夜培養再將培養液滴〇.〇4ml於disc上, 待disc完全吸收菌體後將disc貼於plate上,2〜3天後觀察其抑制圈之大小。 如A3所示,體外實驗證實優酪乳中的B菌可以有效抑制幽門螺懸桿菌的生 200409597 長,且濃度越高抑制效果越佳,但優酪乳其他的乳酸菌如·Α菌、嗜熱鏈球 菌、保加利亞桿菌皆無此效果。 A3 ; Β菌對胃幽門螺旋桿菌之想外抑制圈實驗 2J _ 吻2 _ 苕 ' 奪 0 L l-Ι I I I m 1 I I H Μ Μ I Μ M I m Μ M I I,,,, t. f,, Μ π (11 ( —^ = 只洪完豸 B菌的濃度(108CFU) 4·優酪乳的抑菌測試 將適量✓農度的優絡乳如(0·1〜5ml)與培養基(含胎牛血清)進行混合,待培養基 凝膠後,滴入5//1具活性的幽門螺旋桿菌臨床菌株i與2 ,用分光光度計 測定調整菌數,菌數約為lx l〇8CFU/m卜再以特殊氣體培養,培養2〜3 天,之後觀察幽門螺旋桿菌是否生長,若無生長即判定此濃度優酪乳具有 抑制HP之功效。 表一優酪乳對胃幽門螺旋桿菌的艟外抑菌實驗 無B菌之優酪乳(只有三株菌) 含四株菌之優酪乳 HP臨床菌株 1 &gt;5ml皆無抑菌效果 只要0.125ml就有抑菌效果 HP臨床菌株 2 &gt;5ml皆無抑菌瓦系--- 只要0.125ml就有抑菌效果 添加BifiM沉teria lactis Bb-12 與没有添加 md〇bacteria lactis Bb_12 之優絡 乳相比較;可以破定B菌的存在的確是具功效性的有效成分。 【圖式簡單說明】 2004095973. Lactobacillus susceptibility test: Spread HP clinical strain No. 1 on brucella agar, and then cultivating different lactic acid bacteria A, B, Streptococcus thermophilus, and Bulgarian bacteria overnight, and then drop the culture solution in 0.4 ml. On the disc, after the disc has completely absorbed the bacteria, the disc is attached to the plate, and the size of the inhibition circle is observed after 2 to 3 days. As shown by A3, in vitro experiments have confirmed that B bacteria in Yogurt can effectively inhibit the growth of H. pylori, and the higher the concentration, the better the inhibitory effect. However, other lactic acid bacteria such as · A, thermophilic in Yogurt Neither streptococci nor bulgaric bacteria have this effect. A3; Beta-inhibition experiment of Helicobacter pylori in stomach 2J _ kiss 2 _ 苕 ′ 0 L l-III III m 1 IIH Μ Μ MI Μ MI Μ MII ,,,, t. F ,, Μ π (11 (— ^ = only the concentration of B bacteria (108CFU) in Hongwan 优) 4. The antibacterial test of yogurt will be appropriate ✓ Agronomic superior milk such as (0.1 · 5ml) and culture medium (including fetal bovine Serum) were mixed. After the culture medium was gelled, 5 // 1 of the active H. pylori clinical strains i and 2 were added dropwise. The number of bacteria was adjusted and determined by a spectrophotometer. The number of bacteria was approximately 1 × 108 CFU / m. Cultivate with special gas for 2 ~ 3 days, and then observe whether H. pylori grows. If there is no growth, it is judged that this concentration of buttermilk has the effect of inhibiting HP. Bacterial-free yoghurt with no B strain (only three strains) There are four strains of yoghurt-free HP clinical strain 1 &gt; 5ml have no bacteriostatic effect as long as 0.125ml has bacteriostatic effect HP clinical strain 2 &gt; 5ml have no inhibitory effect Bacterial tile system --- As long as 0.125ml, it has the antibacterial effect. It is better to add BifiM Shenteria lactis Bb-12 and md〇bacteria lactis Bb_12. Comparing the milk;. B may be present in a given break bacteria is indeed the effectiveness of the active ingredient with the drawings briefly described [200,409,597] 本發明係於一般優酪乳之配方製程中,添加雙岐桿菌 /W/5劢-仰l〇5CFU/m卜109CFU/ml進行發酵,並添加半乳糖寡糖0.02% 一0.08% ,以有效維持B菌在保存末期的菌數,且幫助B菌發揮益生菌功 效,達到抑制胃幽門螺旋桿菌之優酪乳配方。 200409597In the present invention, in the formula manufacturing process of general buttermilk, Bifidobacterium / W / 5 劢 -yang 105CFU / m 109CFU / ml is added for fermentation, and galactooligosaccharide 0.02% to 0.08% is added to effectively It maintains the bacteria count of B bacteria at the end of storage, and helps B bacteria to exert the effect of probiotics, so as to achieve an excellent buttermilk formula for inhibiting gastric Helicobacter pylori. 200409597 1 · 一種可抑制胃幽門螺旋桿菌之優酪乳配方,其配方係添加水份60°/〇、 含有水溶解乳蛋白0.16%、脂肪分離的生乳23%、脫脂奶粉7.8%與酵母粉 0.09%,於發酵冷卻後再加入糖液進行混合,此糖液為特砂5.2%、果膠 0.5%、高果糖液糖3.2°/〇、半乳糖寡醣0.02%—0.08%、雙岐桿菌 拙-切105CFU/ml — 10 9 CFU/ml,其特徵在於添加雙岐桿菌 (5垆也詒/沉沿劢-72) 105CFU/ml — 109CFU/ml及添加半乳糖募糖 0.02%—0·08°/〇,以有效維持b菌在保存末期的菌數,且幫助b菌發揮益生 菌功效,達到抑制胃幽門螺旋桿菌之優酪乳配方。1. An excellent buttermilk formula capable of inhibiting Helicobacter pylori, which is formulated by adding water 60 ° / 〇, containing water-soluble milk protein 0.16%, fat separated raw milk 23%, skimmed milk powder 7.8% and yeast powder 0.09% After the fermentation is cooled, sugar solution is added and mixed. The sugar solution is 5.2% special sand, 0.5% pectin, high fructose liquid sugar 3.2 ° / 〇, galactooligosaccharide 0.02% -0.08%, bifidobacteria Cut 105CFU / ml — 10 9 CFU / ml, which is characterized by the addition of bifidobacteria (5 垆 诒 / Shen Yan 劢 -72) 105CFU / ml — 109CFU / ml and the addition of galactose to raise sugar 0.02%-0 · 08 ° / 〇, in order to effectively maintain the number of B bacteria at the end of storage, and help B bacteria to play a probiotic effect, to achieve inhibition of Helicobacter pylori gastric milk formula.
TW91134913A 2002-12-02 2002-12-02 A yogurt formula capable of inhibiting H. pylori TWI252736B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW91134913A TWI252736B (en) 2002-12-02 2002-12-02 A yogurt formula capable of inhibiting H. pylori

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW91134913A TWI252736B (en) 2002-12-02 2002-12-02 A yogurt formula capable of inhibiting H. pylori

Publications (2)

Publication Number Publication Date
TW200409597A true TW200409597A (en) 2004-06-16
TWI252736B TWI252736B (en) 2006-04-11

Family

ID=37564855

Family Applications (1)

Application Number Title Priority Date Filing Date
TW91134913A TWI252736B (en) 2002-12-02 2002-12-02 A yogurt formula capable of inhibiting H. pylori

Country Status (1)

Country Link
TW (1) TWI252736B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113736683A (en) * 2020-08-03 2021-12-03 郑州大学 Streptococcus thermophilus for inhibiting helicobacter pylori and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113736683A (en) * 2020-08-03 2021-12-03 郑州大学 Streptococcus thermophilus for inhibiting helicobacter pylori and application thereof

Also Published As

Publication number Publication date
TWI252736B (en) 2006-04-11

Similar Documents

Publication Publication Date Title
US11116806B2 (en) Composite probiotic lactic acid bacteria powder and preparation method and use thereof
JP6494859B2 (en) Composition comprising a bacterial strain
JP6441536B2 (en) Composition comprising a bacterial strain
Bouvier et al. Effects of consumptionof a milk fermented by the probiotic strain bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans
RU2725883C2 (en) Composition for reducing intestinal gas production
KR101474188B1 (en) Probiotics for use in reducing the incidence and duration of illness
CN109497149A (en) A kind of compound probiotic Yoghourt and preparation method thereof
CN113632841A (en) Compound yogurt with constipation improving effect, and preparation method and application thereof
CN111493261A (en) Probiotic solid beverage for relieving or treating constipation symptom
CN111011493A (en) Preparation method of solidified fermented milk rich in animal bifidobacterium and fermented milk prepared by preparation method
CN102438638B (en) Prevention and treatment of obesity and metabolic diseases induced by obesity using microorganisms
TWI404540B (en) A novel strain of lactobacillus plantarum lp23 and its use in inhibition of helicobacter pylori
EP2076139B1 (en) Probiotic strain lactobacillus delbrueckii subsp . bulgaricus
KR20130130253A (en) Method for manufacturing lactic acid fermented paecilomyces japonica improving intestinal motility
TW200409597A (en) A yogurt formula capable of inhibiting H. pylori
CN112779196B (en) Composite probiotic preparation for reducing constipation incidence of sows and preparation method and application thereof
TWI792249B (en) Treatment and/or prevention of helicobacter pylori infection-related diseases with fermented culture of lactic acid bacteria strains
RU2584600C2 (en) L.bulgaricus STRAIN CAPABLE OF INHIBITING ADHESION OF H.pylori STRAINS TO EPITHELIAL CELLS
CN116076729A (en) Composition, and food and medicine containing the same
TWI434694B (en) A novel strain of lactobacillus acidophilus la27 and its use in inhibition of helicobacter pylori
TW201124146A (en) Food and pharmaceutical composition with strains of lactic acid bacteria for treatment of gastric ulcer
TW201815290A (en) Yogurt fermentation bacteria, whole bacteria yoghurt, and manufacturing method of whole bacteria yogurt enabling bacteria to grow in a balanced manner, complement one another, and prevent individual colonies from being dissolved and destroyed by digestive fluids when passing through the digestive tract
Hovhannisyan et al. Human Milk’s Microbial Population Behavior In Vivo and Ex Vivo
Danielyan et al. New generation of functional yogurts fermented with probiotic lactic acid bacteria isolated from human milk
CN117296922A (en) Fermented milk for improving depression symptoms and preparation method and application thereof

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent